33
Participants
Start Date
July 31, 2017
Primary Completion Date
April 18, 2019
Study Completion Date
August 9, 2019
durvalumab
Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
Tremelimumab
Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
Thomas Jefferson University, Philadelphia
UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville
UF Health Shands Cancer Hospital, Gainesville
UF Health Shands Hospital, Gainesville
University of Florida, Gainesville
University of Florida Health Cancer Center at Orlando Health, Orlando
Trinity Health Michigan, Ann Arbor
University of Michigan, Ann Arbor
St. Joseph Mercy-Brighton, Brighton
St Joseph Mercy-Chelsea, Chelsea
St. Joseph Mercy-Canton, Canton
Cancer Care Specialists of Central Illinois-Swansea, Swansea
Cancer Care Specialists of Central Illinois/Crossroads Cancer Center, Effingham
Cancer Care Specialists of Central Illinois, Decatur
Centralia Oncology Clinic, Centralia
City of Hope, Duarte
Smilow Cancer Hospital at Yale-New Haven, New Haven
Smilow Cancer Hospital Care Center at North Haven, North Haven
NSABP Foundation Inc
NETWORK